Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    82
    ...
ATC Name B/G Ingredients Dosage Form Price
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 156,288 L.L
C07AB03 APO-ATENOL G Atenolol - 50mg 50mg Tablet 327,898 L.L
C10AX09 XIMACOL G Ezetimibe - 10mg 10mg Tablet 1,894,818 L.L
G04CA04 SILODOSINE ARROW G Silodosine - 8mg 8mg Capsule 732,394 L.L
J01DC10 CEFPROZ 250 G Cefprozil - 250mg/5ml 250mg/5ml Powder for suspension 712,237 L.L
J01MA12 LEVOKEY 500 G Levofloxacin (hemihydrate) - 500mg 500mg Tablet, film coated 141,103 L.L
L01EF01 PALBOMED G Palbociclib - 125mg 125mg Capsule 25,799,521 L.L
N03AX11 TOPIRAMATE ARROW G Topiramate - 100mg 100mg Tablet, film coated 1,440,599 L.L
N05BA12 ALPRAZOLAM BIOGARAN G Alprazolam - 0.25mg 0.25mg Tablet, scored 115,570 L.L
P01BA02 CORVAQUINE G Hydroxychloroquine sulfate - 200mg 200mg Tablet, film coated 1,087,873 L.L
R05X COLDIN G Caffeine - 30mg, Noscapine - 10mg, Pseudoephedrine HCl - 30mg, Pyrilamine maleate (Mepyramine) - 15mg, Paracetamol - 300mg Capsule 386,515 L.L
V03AC03 DEFIROX G Deferasirox - 500mg 500mg Tablet, dispersible 38,502,953 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 355,798 L.L
A10BA02 DIANORM XR 1000 G Metformin HCl - 1,000mg 1,000mg Tablet, film coated, extended release 579,772 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 165,482 L.L
C07AB03 ATENOLOL BIOGARAN G Atenolol - 50mg 50mg Tablet, scored 295,645 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet 544,256 L.L
C10AX09 ZEMIL G Ezetimibe - 10mg 10mg Tablet 944,529 L.L
G04CA04 SILODOSINE BIOGARAN G Silodosine - 8mg 8mg Capsule 555,007 L.L
J01DC10 CEFPROZ 250 G Cefprozil - 250mg/5ml 250mg/5ml Powder for suspension 1,343,843 L.L
J01MA12 LEVOMED G Levofloxacin (hemihydrate) - 500mg 500mg Tablet 849,820 L.L
L01EF01 PALBRANCE 125 G Palbociclib - 125mg 125mg Capsule 69,032,469 L.L
N01BB54 PRILA G Prilocaine - 2.5% w/w, Lidocaine - 2.5% w/w Cream 1,057,604 L.L
N03AX11 TOPIRATE 100 BENTA G Topiramate - 100mg 100mg Tablet, film coated 2,559,700 L.L
N05BA12 ALPROX G Alprazolam - 1mg 1mg Tablet 895,895 L.L
P01BA02 DOLQUINE G Hydroxychloroquine sulfate - 200mg 200mg Tablet, coated 1,191,988 L.L
R05X COLD-MED G Caffeine - 30mg, Noscapine - 10mg, Pseudoephedrine HCl - 30mg, Pyrilamine Maleate (Mepyramine) - 15mg, Paracetamol - 300mg Capsule 386,515 L.L
V03AC03 DIFIRAX G Deferasirox - 500mg 500mg Tablet, dispersible 38,637,010 L.L
L01CD02 DOCETAXEL EBEWE G Docetaxel - 80mg/8ml 80mg/8ml Injectable solution L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 2,557,140 L.L
    ...
    82
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026